-
NMPA Released Announcement on the Application of 13 ICH Guidelines Including S1A: Guideline on the Need for Carcinogenicity Studies of Pharmaceuticals
2019-11-12
On November 12, 2019, NMPA issued the Announcement on the Application of 13 ICH Guidelines Including S1A: Guideline on the Need for Carcinogenicity Studies of Pharmaceuticals.
-
CPC Central Committee and the State Council Issued Opinions on Facilitating the Inheritance, Innovation and Development of Traditional Chinese Medicine
2019-10-29
Recently, the Central Committee of the Communist Party of China and the State Council issued the Opinions on Facilitating the Inheritance, Innovation and Development of Traditional Chinese Medicine (hereinafter referred to as Opinions), proffering 20 suggestions from 6 aspects.
-
NMPA issued the Announcement on the Annual Report for National ADR Monitoring (2018)
2019-10-18
On October 18, 2019, NMPA issued the Announcement on the Annual Report for National ADR Monitoring (2018).
-
NMPA Issued the Technical Guidelines for Endpoints in Clinical Trials for Advanced Non-Small Cell Lung Cancer
2019-09-18
NMPA has organized the formulation of and released on September 18, 2019 the Technical Guidelines for Endpoints in Clinical Trials for Advanced Non-Small Cell Lung Cancer.
-
NMPA Issued the Announcement on Registration Application Situation and Self-Examination & Verification of Drug Clinical Trial Data
2019-10-15
On October 15, 2019, NMPA released the Announcement on Registration Application Situation and Self-Examination & Verification of Drug Clinical Trial Data with decision made to verify the clinical trial data of 7 newly received registration applications for drugs that have completed the clinical trials and are applying for production.
